Bone mineral density in glycogen storage disease type Ia and Ib. - Wikidata - awgldk - TriplyDB

Bone mineral density in glycogen storage disease type Ia and Ib.

Bone mineral density in glycogen storage disease type Ia and Ib.

http://www.wikidata.org/entity/Q37446335

about

High Incidence of Serologic Markers of Inflammatory Bowel Disease in Asymptomatic Patients with Glycogen Storage Disease Type Ia.Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease Type I.Aggressive therapy improves cirrhosis in glycogen storage disease type IX.Glycogen Storage Disease type 1a - a secondary cause for hyperlipidemia: report of five cases.Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics.Prevention of complications in glycogen storage disease type Ia with optimization of metabolic control.Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy.Bone health in patients with inborn errors of metabolism

P2860

Q36090555-F6E0C77E-931B-4261-BAF0-D73CA02B424A Q36894716-D38C4A8E-967B-478A-8146-F0F23ADC3F3A Q36902007-C034CBEB-7D55-4184-BDD4-23F86D7AB13F Q36944402-3EC8CAE4-6F34-48A3-ABF5-220079249876 Q38263927-C0435FB4-4848-4E9D-8F20-5C3042E22DAD Q39343139-63509484-DA9C-4E4A-AB56-C4EF90D09FC0 Q50945731-B5395367-27DA-4F27-A07E-7CBACDDCAEE9 Q58744635-F21C9BE6-B23D-405C-9473-68DE65CADB66

P2860

Bone mineral density in glycogen storage disease type Ia and Ib.

http://www.wikidata.org/entity/Q37446335

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 April 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Bone mineral density in glycogen storage disease type Ia and Ib.

@en

Bone mineral density in glycogen storage disease type Ia and Ib.

@nl

type

label

Bone mineral density in glycogen storage disease type Ia and Ib.

@en

Bone mineral density in glycogen storage disease type Ia and Ib.

@nl

prefLabel

Bone mineral density in glycogen storage disease type Ia and Ib.

@en

Bone mineral density in glycogen storage disease type Ia and Ib.

@nl

P1433

Q37446335-EDA721AD-0ECE-4B04-BAAA-5D6E00146620

P1476

Q37446335-641B7988-F459-48C3-8108-51F6C608ACD6

P2093

Q37446335-346D33B2-29D7-4274-942A-C582BC10815F

Q37446335-4EED5395-E35F-4CA0-8724-0BD0E4DDBD7E

Q37446335-64EA2520-CA83-4AA3-BFBB-FE659C761534

Q37446335-77826444-6558-4AB3-BE13-2C8596878084

P2860

Q37446335-062B59A0-74AA-4133-B098-F9CE864A374B

Q37446335-1D0C9017-1583-4E66-8620-2EC5EDD38F52

Q37446335-27EB1445-0EAD-4CAE-97CF-C1AFAECDEF83

Q37446335-6020B9A7-0B9F-4C83-8064-592A76C679B2

Q37446335-64E5C17C-CFCE-47AC-AD38-90592F435F0B

Q37446335-7D05BDDD-2638-40C7-BC34-C93ABDF0C507

Q37446335-ACD218EE-14CD-480D-B500-93C425A16D9B

Q37446335-C9F0377B-A7A0-4EEF-B3B2-AB1E65CA4527

Q37446335-D10BD643-1F3D-446E-A98C-E3D644591D4A

Q37446335-E7EE0EDC-E8FA-4863-9F41-07CE2D86DBF7

P2888

Q37446335-129A8E2E-8222-42F7-B643-BB50BAF5EF89

P31

Q37446335-8622AA0C-8C94-4287-8BF4-B900C2061105

P356

Q37446335-51EF5F8B-7A96-4B46-8C9C-AF25AC2B63B2

P407

Q37446335-5AD19481-846B-4ED1-B306-E3D8B2B10EC3

P577

Q37446335-F52C2FA1-9A0B-49C0-A8C7-C4EE36CDA573

P5875

Q37446335-FA90132C-D27D-4897-9913-1F74026E7322

P698

Q37446335-16239735-A083-464E-9560-BC2D56C91A82

P932

Q37446335-2282E2CB-5C6C-489C-98B8-BBC3750CF2CF

P356

P1433

Genetics in Medicine

P1476

Bone mineral density in glycogen storage disease type Ia and Ib.

@en

P2093

Alexander Kirpich

http://www.w3.org/2001/XMLSchema#string

David A Weinstein

http://www.w3.org/2001/XMLSchema#string

Laurie A Minarich

http://www.w3.org/2001/XMLSchema#string

Laurie M Fiske

http://www.w3.org/2001/XMLSchema#string

P2860

Natural history of hepatocellular adenoma formation in glycogen storage disease type I

Acidosis inhibits osteoblastic and stimulates osteoclastic activity in vitro.

Glycogen storage diseases.

Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density.

Bone mineralisation in type 1 glycogen storage disease.

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition.

Defective neutrophil and monocyte functions in glycogen storage disease type Ib: a literature review.

Low bone mass in glycogen storage disease type 1 is associated with reduced muscle force and poor metabolic control.

Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease.

P2888

P31

scholarly article

P356

10.1038/GIM.2012.36

http://www.w3.org/2001/XMLSchema#string

P407

P577

2012-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223962694

http://www.w3.org/2001/XMLSchema#string

P698

22481133

http://www.w3.org/2001/XMLSchema#string

P932

3884026

http://www.w3.org/2001/XMLSchema#string